Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
Department of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Biosensors (Basel). 2022 Aug 8;12(8):617. doi: 10.3390/bios12080617.
Immunotherapy is one of the four pillars of cancer treatment that has recently emerged as a beacon of hope for cancer patients. Certain immunotherapies, for example, immune checkpoint inhibitor therapy, monoclonal antibody therapy and chimeric antigen T-cell therapy have garnered extensive interest in response to their exceptional properties that activate the immune system to respond to cancer cells, inhibiting their progression. In the era of rapid development, dostarlimab, an anti-programmed cell death protein (PD-1) monoclonal antibody has mesmerized the medical profession by showing complete (100%) cure of patients with colorectal cancer. Not only this, the results obtained from clinical trials revealed no major side effects in any of the participants in the study. Dostarlimab has also shown promising results in endometrial cancer, ovarian cancer, melanoma, head and neck cancer, and breast cancer therapy. This review focuses upon the action of immunotherapy, extensively emphasizing the miraculous therapy to activate T-cells for cancer treatment. Based on this, we discuss major ongoing clinical trials and combination immunotherapies to enlighten future clinicians and researchers about the response of dostarlimab against various cancers.
免疫疗法是癌症治疗的四大支柱之一，最近它作为癌症患者的希望灯塔而出现。某些免疫疗法，例如免疫检查点抑制剂疗法、单克隆抗体疗法和嵌合抗原 T 细胞疗法，因其能够激活免疫系统对癌细胞产生反应、抑制其进展的特殊性质而引起了广泛关注。在快速发展的时代，抗程序性细胞死亡蛋白 1（PD-1）单克隆抗体 dostarlimab 通过显示出结直肠癌患者的完全（100%）治愈，令医学界为之着迷。不仅如此，临床试验的结果显示，研究中的参与者均没有出现主要的副作用。dostarlimab 在子宫内膜癌、卵巢癌、黑色素瘤、头颈部癌和乳腺癌治疗中也显示出了良好的效果。本综述重点讨论了免疫疗法的作用，广泛强调了激活 T 细胞治疗癌症的神奇疗法。基于这一点，我们讨论了主要的正在进行的临床试验和联合免疫疗法，以启发未来的临床医生和研究人员了解 dostarlimab 对各种癌症的反应。
